A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Conditions
- Gastric Adenocarcinoma
- Adenocarcinoma of the Gastroesophageal Junction
- Non-small Cell Lung Cancer
- Carcinoma, Transitional Cell
- Biliary Tract Cancer
Interventions
- DRUG: Ramucirumab
- DRUG: Pembrolizumab
Sponsor
Eli Lilly and Company
Collaborators